Pirrotta, Paola http://orcid.org/0000-0002-1465-4529
Tavares-Da-Silva, Fernanda http://orcid.org/0000-0003-2411-8065
Co, Maribel http://orcid.org/0000-0002-0208-9649
Lecrenier, Nicolas http://orcid.org/0000-0002-0321-6283
Hervé, Caroline http://orcid.org/0000-0002-0794-8748
Stegmann, Jens-Ulrich http://orcid.org/0000-0002-3792-4368
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
Article History
Accepted: 31 August 2021
First Online: 7 October 2021
Declarations
:
: This work was supported by GlaxoSmithKline Biologicals SA, including all costs associated with the development and publication of this manuscript.
: Maribel Co, Caroline Hervé, Nicolas Lecrenier, Paola Pirrotta, Jens-Ulrich Stegmann, and Fernanda Tavares-Da-Silva were employees of the GSK group of companies at the time the analysis was designed, initiated, and/or conducted. Caroline Hervé is currently an employee of UCB Pharma and has stock options in UCB Pharma. Jens-Ulrich Stegmann and Fernanda Tavares-Da-Silva hold shares in the GSK groups of companies as part of their employee remuneration. The authors have no other non-financial relationships and activities or conflicts of interest.
: Not applicable
: Not applicable
: Shingrix is a trademark owned by or licensed to the GSK group of companies. MedDRA<sup>®</sup> is a trademark registered by IFPMA on behalf of ICH.
: The data that support the findings of this work are available from the corresponding author on reasonable request.
: Not applicable
: Conceptualisation: MC, CH, NL, PP, JUS, and FTDS. Validation: MC, CH, NL, PP, JUS, and FTDS. Formal analysis: MC and PP. Investigation: MC, CH, NL, PP, and FTDS. Resources: MC, NL, PP, and FTDS. Writing (original draft): PP. Visualisation: NL, PP, and FTDS. Supervision: JUS and FTDS. All authors contributed to the writing (review and editing) of the manuscript and approved the final version.